Sinovac Biotech SVA Institutional Ownership

Updated Oct 5, 2026

Sinovac Biotech Ltd (NASDAQ:SVA) appeared in the 13F filings of 29 institutional investors for the quarter ended June 30, 2026.

• These investors held 14.57% of Sinovac Biotech's outstanding shares at the end of Q2 2026, up from 14.55% in Q1 2026.
• Total holdings of SVA shares rose 0.12% from Q1 2026, and the holder count rose 7.41% from Q2 2025.
• Of the 29 holders of SVA in Q2 2026, 7 added to their positions, 4 reduced their stakes and 18 left their positions unchanged.
• In total, institutional investors held 10.47Mn shares of Sinovac Biotech at the end of Q2 2026, up 12.16K from the prior quarter and down 10.68K from a year earlier.
• Vivo Capital, LLC was the top holder of Sinovac Biotech as of June 30, 2026, with 5.9Mn shares, or 8.21% of shares outstanding.
• Holders that added the most shares of Sinovac Biotech in Q2 2026 were UBS Group AG (+250 shares), Assetmark, Inc (+37 shares) and Morgan Stanley (+2 shares).
• On the other side, among holders that kept a position in Sinovac Biotech, the largest reductions in Q2 2026 came from Osaic Holdings, Inc. (-1.2K shares), Wells Fargo & Company (-231 shares), Horizon Investments, LLC (-52 shares) and Harbour Investments, Inc. (-5 shares).
• Per Business Quant, the top 10 investors in SVA for the quarter ended June 30, 2026 were Vivo Capital, LLC (5.9Mn shares), OrbiMed Advisors LLC (2.72Mn shares), Renaissance Technologies LLC (1.31Mn shares), Neumann Advisory Hong Kong Ltd (315.59K shares), California Public Employees Retirement System (68.73K shares), Skandinaviska Enskilda Banken AB (40K shares), Spark Investment Management LLC (29.1K shares), Geode Capital Management, LLC (27.72K shares), Susquehanna International Group, LLP (16.43K shares) and Navellier & Associates Inc (13.02K shares).